New BPH guidelines endorse combination drug therapy for select patients

>Chicago­Combination drug therapy for benign prostatic hyperplasiahas won the endorsement of the American Urological Association in the organization'sfirst-ever clinical guidelines for the management of BPH.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria